Incyte Genomics Inc
$126.27
$1.52 (+1.22%)
$125.10Day Range$126.69
Key Statistics
Market Cap
$25.29B
Shares Outstanding
202.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 3, 1993
Round Lot
100
Locale
US
Trading Data
Day Open
$125.74
Day High
$126.69
Day Low
$125.10
Volume
420.4K
VWAP
$126.13
Prev Close
$124.75
Transactions
--
Acc. Volume
--
About Incyte Genomics Inc
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCHSIC 87312,844 employees1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803(302) 498-6700IPO Nov 3, 1993US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000879169
- Composite FIGI
- BBG000BNPSQ9
- Share Class FIGI
- BBG001S8Q6N2
- Ticker Root
- INCY
- SIC Code
- 8731
About Incyte Genomics Inc (INCY) Stock
Incyte Genomics Inc (INCY) closed the 2026-09-17 session at $126.27, up 1.22% versus the previous close (+1.52). The stock opened at $125.74 and traded between $125.10 and $126.69 during that session. Session trading volume was 420K shares. The volume-weighted average price (VWAP) is $126.13.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Incyte Genomics Inc has a market capitalization of $25.29 billion. The company operates in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry classification. INCY is listed on the XNAS exchange. The company employs approximately 2,844 people. Incyte Genomics Inc is headquartered in WILMINGTON, DE. The recorded listing date is 1993-11-03.
On this page you can find market INCY stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector.